Cargando…
Long Term Cyclic Pamidronate Reduces Bone Growth by Inhibiting Osteoclast Mediated Cartilage-to-Bone Turnover in the Mouse
Bisphosphonates, used to treat diseases exhibiting increased osteoclast activity, reduce longitudinal bone growth through an as yet undefined mechanism. Pamidronate, an aminobisphosphonate, was given weekly to mice at 0, 1.25, or 2.50 mg/kg/wk beginning at 4 weeks of age. At 12 weeks of age, humeral...
Autores principales: | Evans, K.D, Sheppard, L.E, Grossman, D.I, Rao, S.H, Martin, R.B, Oberbauer, A.M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703200/ https://www.ncbi.nlm.nih.gov/pubmed/19572021 http://dx.doi.org/10.2174/1874325000802010121 |
Ejemplares similares
-
Pamidronate Alters the Growth Plate in the Oim Mouse Model for Osteogenesis Imperfecta
por: Evans, K. D., et al.
Publicado: (2009) -
TURNOVER OF THE ORGANIC MATRIX OF CARTILAGE AND BONE AS VISUALIZED BY AUTORADIOGRAPHY
por: Campo, Robert D., et al.
Publicado: (1963) -
High-dose intravenous pamidronate for metastatic bone pain.
por: Purohit, O. P., et al.
Publicado: (1994) -
Metabolic effects of pamidronate in patients with metastatic bone disease.
por: Vinholes, J., et al.
Publicado: (1996) -
Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.
por: Clarke, N. W., et al.
Publicado: (1991)